SAB Biotherapeutics Announces $85M Public Offering of Common Stock and Pre-Funded Warrants.

SAB Biotherapeutics, a clinical-stage biopharmaceutical company, has closed an $85 million public offering of common stock and pre-funded warrants. The gross proceeds will fund the development of its clinical-stage product candidate, SAB-142, and related activities. Jefferies, UBS Investment Bank, Citigroup, and Barclays acted as joint book-running managers, with Chardan as lead manager. The company plans to use the net proceeds for ongoing and planned clinical trials, manufacturing, regulatory, and operational activities, as well as working capital and general corporate purposes.